TNF and Cowden disease: Infliximab (IFX) is an anti-tumor necrosis factor-α (anti-TNF-α) monoclonal antibody that has been shown to be effective and well tolerated in the treatment of adult and pediatric CD in randomized controlled trials [15,16], and has been approved for the treatment of adult and pediatric CD outside of Japan.